Related references
Note: Only part of the references are listed.Impact of Renal Function on the Pharmacokinetics and Safety of Ceftolozane-Tazobactam
Myra Wooley et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Multicenter, Double-Blind, Randomized, Phase II Trial To Assess the Safety and Efficacy of Ceftolozane-Tazobactam plus Metronidazole Compared with Meropenem in Adult Patients with Complicated Intra-Abdominal Infections
Christopher Lucasti et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012)
Helio S. Sader et al.
JOURNAL OF INFECTION (2014)
In Vivo Activities of Ceftolozane, a New Cephalosporin, with and without Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, Including Strains with Extended-Spectrum β-Lactamases, in the Thighs of Neutropenic Mice
W. A. Craig et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Ceftolozane in an In Vitro Infection Model
Brian VanScoy et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2011-2012)
David J. Farrell et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Pharmacological Basis of β-Lactamase Inhibitor Therapeutics: Tazobactam in Combination with Ceftolozane
Brian VanScoy et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
How should we dose antibiotics for pneumonia in the ICU?
Andrew A. Udy et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2013)
Pharmacokinetics and Safety of Intravenous Ceftolozane-Tazobactam in Healthy Adult Subjects following Single and Multiple Ascending Doses
Benjamin Miller et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects
Gurudatt Chandorkar et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
Pharmacokinetics of Beta-Lactam Antibiotics in Patients with Intra-Abdominal Disease: A Structured Review
Syamhanin Adnan et al.
SURGICAL INFECTIONS (2012)
Antimicrobial Activity of CXA-101, a Novel Cephalosporin Tested in Combination with Tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis Strains Having Various Resistance Phenotypes
Helio S. Sader et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14-and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae
Emilia Titelman et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2011)
Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of beta-lactams
Joao Goncalves-Pereira et al.
CRITICAL CARE (2011)
Affinity of the New Cephalosporin CXA-101 to Penicillin-Binding Proteins of Pseudomonas aeruginosa
Bartolome Moya et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Pharmacokinetics and Safety of CXA-101, a New Antipseudomonal Cephalosporin, in Healthy Adult Male and Female Subjects Receiving Single- and Multiple-Dose Intravenous Infusions
Yigong Ge et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Stability of FR264205 against AmpC β-lactamase of Pseudomonas aeruginosa
Shinobu Takeda et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2007)
Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check
Y Yano et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2001)
Share Paper
